Advicenne S.A.
ALDVI.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.59M
Close$
Share Statistics
| Market cap | $9.59 Million |
|---|---|
| Enterprise Value | $29.22 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.72 |
| Beta | 0.97 |
| Outstanding Shares | 14,431,000 |
Return
| Return on Equity | 27.04% |
|---|---|
| Return on Assets | -77.47% |
| Return on Invested Capital | -535.60% |
Valuation & Multiples
| P/E Ratio | 221.16 |
|---|---|
| PEG | -114.5 |
| Price to Sales | - |
| Price to Book Ratio | -0.32 |
| Enterprise Value to Revenue | 2.39 |
| Enterprise Value to EBIT | 14.82 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.72 |
| Debt to Equity | -0.98 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$2.70 M
Average shareholder expectationNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Advicenne S.A.
11 employees
CEO: Didier Laurens Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal r...